Related Experiment Video
Updated: Aug 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from
Sophie Gottschalk1, Shinwan Kany2,3, Hans-Helmut König1
1Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martinistraße 52 Building W37, 20246 Hamburg, Germany.
Insights
Early rhythm control (ERC) in atrial fibrillation patients is cost-effective, offering significant health benefits at reasonable costs. The probability of ERC being cost-effective is high at a willingness-to-pay threshold of €55,000 per life year gained.
Area of Science:
- Cardiology
- Health Economics
Background:
- The EAST-AFNET 4 trial demonstrated that early rhythm control (ERC) reduces major adverse cardiovascular outcomes by approximately 20%.
- The cost-effectiveness of implementing ERC compared to usual care requires thorough evaluation from a healthcare system perspective.
Purpose of the Study:
- To assess the cost-effectiveness of early rhythm control (ERC) versus usual care for patients with atrial fibrillation.
- To determine the incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves (CEACs) for ERC.
Main Methods:
- A within-trial cost-effectiveness analysis using data from the German subsample of the EAST-AFNET 4 trial (n=1664).
- Evaluation from a healthcare payer's perspective over a 6-year time horizon, considering hospitalization and medication costs.
- Calculation of ICERs for 'year without a primary outcome' and 'life year gained', alongside CEACs to address uncertainty.
Main Results:
- Early rhythm control (ERC) was associated with higher costs (+€1924) compared to usual care.
- ICERs were calculated at €10,638 per additional year without a primary outcome and €22,536 per life year gained.
- Cost-effectiveness acceptability curves indicated a high probability (≥95% or ≥80%) of ERC being cost-effective at a willingness-to-pay of ≥€55,000.
Conclusions:
- Early rhythm control (ERC) offers potential health benefits at reasonable costs from a German healthcare payer's perspective.
- Cost-effectiveness of ERC is highly probable, particularly at willingness-to-pay thresholds of €55,000 or more.
- Further research is recommended to explore ERC cost-effectiveness in diverse international settings, specific patient subgroups, and varying treatment modalities.
Aims:
The randomized, controlled EAST-AFNET 4 trial showed that early rhythm control (ERC) reduces the rate of a composite primary outcome (cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome) by ∼20%. The current study examined the cost-effectiveness of ERC compared to usual care.
Methods And Results:
This within-trial cost-effectiveness analysis was based on data from the German subsample of the EAST-AFNET 4 trial (n = 1664/2789 patients). Over a 6-year time horizon and from a healthcare payer's perspective, ERC was compared to usual care regarding costs (hospitalization and medication) and effects (time to primary outcome; years survived). Incremental cost-effectiveness ratios (ICERs) were calculated. Cost-effectiveness acceptability curves were constructed to visualize uncertainty. Early rhythm control was associated with higher costs [+€1924, 95% CI (-€399, €4246)], resulting in ICERs of €10 638 per additional year without a primary outcome and €22 536 per life year gained. The probability of ERC being cost-effective compared to usual care was ≥95% or ≥80% at a willingness-to-pay value of ≥€55 000 per additional year without a primary outcome or life year gained, respectively.
Conclusion:
From a German healthcare payer's perspective, health benefits of ERC may come at reasonable costs as indicated by the ICER point estimates. Taking statistical uncertainty into account, cost-effectiveness of ERC is highly probable at a willingness-to-pay value of ≥€55 000 per additional life year or year without a primary outcome. Future studies examining the cost-effectiveness of ERC in other countries, subgroups with higher benefit from rhythm control therapy, or cost-effectiveness of different modes of ERC are warranted.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VII: Nursing Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Dysrhythmias V: Evaluating Dysrhythmias

